Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) EPS (Weighted Average and Diluted) (2024 - 2025)

Historic EPS (Weighted Average and Diluted) for Neuphoria Therapeutics (NEUP) over the last 2 years, with Q4 2025 value amounting to -$0.77.

  • Neuphoria Therapeutics' EPS (Weighted Average and Diluted) rose 5698.32% to -$0.77 in Q4 2025 from the same period last year, while for Dec 2025 it was -$2.61, marking a year-over-year decrease of 5088.11%. This contributed to the annual value of -$4.09 for FY2025, which is 7801.66% up from last year.
  • As of Q4 2025, Neuphoria Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.77, which was up 5698.32% from -$4.41 recorded in Q3 2025.
  • In the past 5 years, Neuphoria Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of $6.55 in Q1 2025 and a low of -$9.34 during Q2 2025